Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the stock.

Oragenics Stock Down 2.7 %

NYSE OGEN opened at $3.19 on Friday. Oragenics has a 12-month low of $2.60 and a 12-month high of $24.00.

Get Oragenics alerts:

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories

• Five stocks we like better than Oragenics
• How to Invest in Cannabis, Step by Step
• MarketBeat Week in Review – 8/7 – 8/11
• Space Investment: How to Invest in Space Exploration
• 3 Retailers To Watch Closely Next Week
• Most Active Stocks: Dollar Volume vs Share Volume
• Investing in Coffee: 3 Great Strategies to Consider

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.